pegaspargase Injectable Solution

Brand(s)
Oncaspar
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Sigma-Tau Pharmaceuticals, Inc. (2015-05-01)
Oldest Current Product
1994-02-01
License(s)
BLA
RxNORM
INJECTABLE SOLUTION\PEGASPARGASE
SPL Active
INTRAMUSCULAR\INJECTION, SOLUTION\PEGASPARGASE
SPL Moiety
INTRAMUSCULAR\INJECTION, SOLUTION\PEGASPARGASE

product(s) by strength(s)

pegaspargase 750 unt/ml injectable solution

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1544820301OncasparBLASigma-Tau Pharmaceuticals, Inc.1994-02-01PEGASPARGASEINTRAMUSCULARINJECTION, SOLUTION103411d933e1d1-06b7-4d70-981f-3e8984b0683f

application(s)

#idtitleapprovedtradenamesfda division
1103411pegaspargase Application1994-02-01OncasparCDER

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
1d933e1d1-06b7-4d70-981f-3e8984b0683f (view SPL)These highlights do not include all the information needed to use Oncaspar safely and effectively. See full prescribing information for Oncaspar. Oncaspar(pegaspargase) injection, for intramuscular or intravenous useInitial U.S. Approval: 1994prescriptionHuman PrescriptionSigma-Tau Pharmaceuticals, Inc.MANUFACTURE2015-05-016544820301

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII